What is Haematologic Technologies?
Headquartered in Essex Junction, Vermont, Haematologic Technologies specializes in offering a comprehensive suite of products and services for biological research. Their offerings include customized blood collection tubes, a wide array of over 150 high-quality blood coagulation products such as proteins, antibodies, and substrates, and contract research and development services. These services encompass custom protein purification, assay development, validation, and GMP release and stability testing, catering to the stringent demands of the pharmaceutical and biotechnology industries. The company's deep expertise in protein biochemistry, with a specific emphasis on blood coagulation, positions it as a key partner for research institutions and diagnostic companies.
How much funding has Haematologic Technologies raised?
Haematologic Technologies has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Haematologic Technologies
PPP
Public-Private Partnership
What's next for Haematologic Technologies?
The recent strategic investment of $350K signals a pivotal moment for Haematologic Technologies, likely enabling the company to accelerate its growth initiatives and expand its service capabilities. Given the 'large-scale late-stage funding' context, this capital infusion is expected to support further scaling of operations, potential expansion into new markets, and continued investment in research and development to enhance its product portfolio and service offerings. The company is poised to leverage this financial backing to solidify its market leadership in specialized protein biochemistry and blood coagulation research solutions.
See full Haematologic Technologies company page
